新股消息 | 科兴制药递表港交所

Core Insights - Kexing Biopharmaceutical Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Jinshi International as the sole sponsor [1] - The company is an innovative and internationally developed biopharmaceutical firm, focusing on the research, production, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies [1] - Kexing is one of the earliest established biopharmaceutical companies in China and is a key industrialization base for the national "863" program [1] Revenue Sources - The main revenue sources during the reporting period include four self-commercialized products and two introduced products: - SINOGEN (Interferon α1b injection) - EPOSINO (Erythropoietin injection) - WHITE-C (Granulocyte colony-stimulating factor injection) - CLOBICO (Clostridium butyricum live bacteria powder/capsule) - Apexelsin (Paclitaxel injection) - Reminton (Infliximab injection) [1]